[go: up one dir, main page]

NO20015054D0 - Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK - Google Patents

Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK

Info

Publication number
NO20015054D0
NO20015054D0 NO20015054A NO20015054A NO20015054D0 NO 20015054 D0 NO20015054 D0 NO 20015054D0 NO 20015054 A NO20015054 A NO 20015054A NO 20015054 A NO20015054 A NO 20015054A NO 20015054 D0 NO20015054 D0 NO 20015054D0
Authority
NO
Norway
Prior art keywords
sgk
inhibitors
drugs
cell volume
human kinase
Prior art date
Application number
NO20015054A
Other languages
English (en)
Other versions
NO20015054L (no
Inventor
Siegfried Waldegger
Carsten Wagner
Stefan Broeer
Karin Klingel
Original Assignee
Lang Florian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lang Florian filed Critical Lang Florian
Publication of NO20015054D0 publication Critical patent/NO20015054D0/no
Publication of NO20015054L publication Critical patent/NO20015054L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20015054A 1999-04-20 2001-10-17 Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK NO20015054L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917990A DE19917990A1 (de) 1999-04-20 1999-04-20 Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
PCT/EP2000/003578 WO2000062781A1 (de) 1999-04-20 2000-04-19 Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk

Publications (2)

Publication Number Publication Date
NO20015054D0 true NO20015054D0 (no) 2001-10-17
NO20015054L NO20015054L (no) 2001-12-14

Family

ID=7905297

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015054A NO20015054L (no) 1999-04-20 2001-10-17 Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK

Country Status (18)

Country Link
EP (1) EP1171131A1 (no)
JP (1) JP2002542196A (no)
KR (1) KR100718900B1 (no)
CN (1) CN1351496A (no)
AU (1) AU779941B2 (no)
BR (1) BR0009914A (no)
CA (1) CA2369078A1 (no)
CZ (1) CZ20013778A3 (no)
DE (1) DE19917990A1 (no)
HU (1) HUP0200819A3 (no)
MX (1) MXPA01010588A (no)
NO (1) NO20015054L (no)
PL (1) PL198427B1 (no)
RU (1) RU2288718C9 (no)
SK (1) SK14972001A3 (no)
UA (1) UA79066C2 (no)
WO (1) WO2000062781A1 (no)
ZA (1) ZA200108610B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
DE10113876A1 (de) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnostische Analyse der Hypertonie
CA2449794A1 (en) * 2001-04-27 2002-11-07 Cold Spring Harbor Laboratory Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity
DE10149393A1 (de) * 2001-09-28 2003-04-24 Florian Lang sgk1 als diagnostisches und therapeutisches target
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
BR0318166A (pt) * 2003-03-03 2006-04-04 Florian Lang uso de uma substáncia para detectar sgk1, kit para essa detecção, bem como composição farmacêutica que inibe ou ativa a sua expressão e/ou função
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
DE10346913A1 (de) * 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
WO2005084702A1 (ja) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
US20070203085A1 (en) * 2004-03-11 2007-08-30 Florian Lang Methods For Interfering With Fibrosis
RU2006135654A (ru) * 2004-03-11 2008-09-10 Мерк Патент ГмбХ (DE) Способы модуляции глутаматных рецепторов для лечения нейропсихиатрических расстройств, включающие применение модуляторов сывороточных и индуцируемых глюкокортикоидами киназ
EP1745294A2 (en) * 2004-04-30 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102004030987A1 (de) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
DE102005001053A1 (de) * 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
DE102005015255A1 (de) 2005-04-04 2006-10-05 Merck Patent Gmbh Acylhydrazide
DE102005035742A1 (de) * 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
DE102005039541A1 (de) * 2005-08-22 2007-03-22 Merck Patent Gmbh 3-Oxo-indazol-quadratsäurederivate
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
DE102008010362A1 (de) * 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
DE102008010363A1 (de) 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 als therapeutisches und diagnostisches Target für karzinomatöse Erkrankungen
DE102008010361A1 (de) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008059133A1 (de) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
EP2637650A2 (en) 2010-11-10 2013-09-18 National Jewish Health Methods to test allergic conditions
CN107875153A (zh) * 2017-11-16 2018-04-06 上海壹志医药科技有限公司 去甲白屈菜红碱的药物用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5874464A (en) * 1995-01-13 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Conformationally constrained diacylglycerol analogues
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
CA2257136C (en) * 1996-05-30 2004-07-20 Hoechst Marion Roussel, Inc. Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales

Also Published As

Publication number Publication date
HUP0200819A2 (hu) 2002-07-29
RU2288718C9 (ru) 2008-04-27
EP1171131A1 (de) 2002-01-16
MXPA01010588A (es) 2004-09-06
DE19917990A1 (de) 2000-11-02
HUP0200819A3 (en) 2009-08-28
JP2002542196A (ja) 2002-12-10
KR20020012172A (ko) 2002-02-15
CZ20013778A3 (cs) 2002-06-12
AU4297200A (en) 2000-11-02
KR100718900B1 (ko) 2007-05-17
PL352547A1 (en) 2003-08-25
RU2288718C2 (ru) 2006-12-10
BR0009914A (pt) 2002-01-08
CA2369078A1 (en) 2000-10-26
ZA200108610B (en) 2002-01-02
SK14972001A3 (sk) 2002-06-04
UA79066C2 (en) 2007-05-25
CN1351496A (zh) 2002-05-29
NO20015054L (no) 2001-12-14
PL198427B1 (pl) 2008-06-30
WO2000062781A1 (de) 2000-10-26
AU779941B2 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
NO20015054D0 (no) Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK
HUP0301005A3 (en) Pirrolotriazine inhibitors of kinases pharmaceutical compositions containing them and their use
HUP0203323A3 (en) Tyrosine kinase inhibitors and pharmaceutical compositions containing them
ATE306487T1 (de) Purinhemmer von cyclinabhängiger kinase 2 und ikb-alpha
HUP0201261A2 (en) Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
ATE380814T1 (de) Kinaseinhibitoren als arzneimittel
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
EP1218013A4 (en) PHOPHOLIPID PRODUCTS OF CELL PROPAGATION INHIBITORS
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
NO20013335L (no) Anvendelse av 4-H-1-benzopyran-4-on-derivater som inhibitorer av glatt muskelcelle proliferering
NO20014858L (no) Anvendelse av CYP2D6 inhibitorer i kombinasjonsterapi
HUP0202708A3 (en) Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
NO20000225D0 (no) Retarderte legemiddelformuleringer inneholdende en kombinasjon av et opioid og en -agonist
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
PL338991A1 (en) Substituted oxindole derivatives as inhibitors of thyrosine kinase protein and serine/threonine kinase protein
CY2013009I2 (el) Παραγωγα ινδαζολης και φαρμακευτικες συνθεσεις για αναστολη των κινασων πρωτεϊνης και μεθοδοι για τη χρηση τους
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
HUP0201214A3 (en) Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
DE60025536D1 (de) Beschichtung von tablettenkernen
NO20020365L (no) Oligonukleotider for inhibiering av ekspresjonen av humant eg5
AU2003256410A1 (en) COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
HUP0202401A2 (en) Five-membered heterocyclic amidinec as prodrugs of thrombin inhibitors, pharmaceutical compositions comprising thereof and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application